Denali Therapeutics Statistics
Want to see DNLI full AI Analyst Report?
Denali Therapeutics (DNLI) Stock Statistics & Valuation Metrics
Total Valuation
Denali Therapeutics has a market cap or net worth of $3.00B. The enterprise value is $3.49B.
- Market Cap
- $3.00B
- Enterprise Value
- $3.49B
Share Statistics
Denali Therapeutics has 160,290,540 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 160,290,540
- Owned by Insiders
- 5.12%
- Owned by Institutions
- 76.59%
Financial Efficiency
Denali Therapeutics’s return on equity (ROE) is -0.51 and return on invested capital (ROIC) is -52.59%.
- Return on Equity (ROE)
- -0.51
- Return on Assets (ROA)
- -0.45
- Return on Invested Capital (ROIC)
- -52.59%
- Return on Capital Employed (ROCE)
- -0.53
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.02M
- Employee Count
- 503
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Denali Therapeutics is -10.83. Denali Therapeutics’s PEG ratio is -0.26.
- PE Ratio
- -10.83
- PS Ratio
- 140.48
- PB Ratio
- 3.81
- Price to FCF
- -6.68
- Price to Operating Cash Flow
- -7.95
- PEG Ratio
- -0.26
Income Statement
In the last 12 months, Denali Therapeutics had revenue of 0 and earned -512.54M in profits. Earnings per share was -2.97.
- Revenue
- 0
- Gross Profit
- -11.18M
- Operating Income
- -555.34M
- Pretax Income
- -512.44M
- Net Income
- -512.54M
- EBITDA
- -497.63M
- Earnings Per Share (EPS)
- -2.97
Cash Flow
In the last 12 months, operating cash flow was -444.19M and capital expenditures -5.80M, giving a free cash flow of -449.99M billion.
- Operating Cash Flow
- -444.19M
- Free Cash Flow
- -449.99M
- Free Cash Flow per Share
- -2.39
Dividends & Yields
Denali Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -14.98%
- Earnings Yield
- -8.91%
Stock Price Statistics
- Beta
- 1.71
- 52-Week Price Change
- 9.27%
- 50-Day Moving Average
- 19.84
- 200-Day Moving Average
- 21.24
- Relative Strength Index (RSI)
- 43.53
- Average Volume (3m)
- 1.62M
Important Dates
Denali Therapeutics upcoming earnings date is Mar 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 03, 2026
- Next Earnings Date
- Mar 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Denali Therapeutics as a current ratio of 9.16, with Debt / Equity ratio of 3.63%
- Current Ratio
- 9.16
- Quick Ratio
- 9.16
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.34
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Denali Therapeutics has paid 102.00K in taxes.
- Income Tax
- 102.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Denali Therapeutics EV to EBITDA ratio is -10.44, with an EV/FCF ratio of -6.99.
- EV to Sales
- 147.13
- EV to EBITDA
- -10.44
- EV to Free Cash Flow
- -6.99
- EV to Operating Cash Flow
- -7.08
Balance Sheet
Denali Therapeutics has $516.20M in cash and marketable securities with $244.90M in debt, giving a net cash position of $271.29M billion.
- Cash & Marketable Securities
- $516.20M
- Total Debt
- $244.90M
- Net Cash
- $271.29M
- Net Cash Per Share
- $1.69
- Tangible Book Value Per Share
- $4.73
Margins
Gross margin is 71.96%, with operating margin of -2488.14%, and net profit margin of -1470.50%.
- Gross Margin
- 71.96%
- Operating Margin
- -2488.14%
- Pretax Margin
- -1470.03%
- Net Profit Margin
- -1470.50%
- EBITDA Margin
- -1409.91%
- EBIT Margin
- -1470.03%
Analyst Forecast
The average price target for Denali Therapeutics is $35.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $35.33
- Price Target Upside
- 88.55% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 8
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 40.59%
Scores
- Smart Score
- 4
- AI Score
- 60

